ClinicalTrials.gg
RecruitingNCT05735184Updated Mar 13, 2026

A Study to Investigate the Safety and Tolerability of Ziftomenib in Combination With Venetoclax/Azacitidine, Venetoclax, 7+3, or 7+3+Quizartinib in Patients With AML

A Phase 1 interventional study of Ziftomenib and Venetoclax in Acute Myeloid Leukemia, Mixed Lineage Leukemia Gene Mutation and Refractory AML, sponsored by Kura Oncology, Inc.. Recruiting at 44 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-03-13.

Sponsored by Kura Oncology, Inc. · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Started Jul 2023; still recruiting 3 years 3 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
420
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 28 studies testing quizartinib in Leukemia, Myeloid, Acute — 6 open to participants now, 10 under way, 2 of them phase 3. quizartinib · Leukemia, Myeloid, Acute.

Planned enrollment
4th of 28
420 · median 69
Started
2023
the only one that year
Phase 1
8 of 28
1 open now
Registered
24th of 28
by date
Lead sponsor
1 of 28
Kura Oncology, Inc.

Among the 28 studies testing quizartinib in Leukemia, Myeloid, Acute, this one is the 4th largest by planned enrollment, is the only one that started in 2023, is one of 8 in phase 1, and was the 24th registered.

Leukemia, Myeloid, Acute

3,669 studies on the registry are indexed under Leukemia, Myeloid, Acute; 817 are open to participants now.

Browse Leukemia, Myeloid, Acute studies →

Open to participants now

6 of the 28 studies testing quizartinib in Leukemia, Myeloid, Acute are open now, in 9 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 6 open studies →

About quizartinib

quizartinib: first FDA approval 2023 (VANFLYTA), first EMA approval 2023. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 625 Leukemia, Myeloid, Acute studies recruiting now, 363 (58%) set no upper age limit and 222 (36%) stop at 75 or younger; 145 take children under 18; 29 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 28 studies testing quizartinib in Leukemia, Myeloid, Acute, or all of them as a file.
02

Study summary

Ziftomenib is an investigational drug in development for the treatment of patients with acute myeloid leukemia (AML) with certain genetic alterations.

This protocol has 3 separate arms that will investigate the benefits and risks of adding ziftomenib to standard-of-care (SOC) drug treatments in patients who have AML with certain genetic mutations. Both newly diagnosed and relapsed refractory patients with AML will be assigned to different cohorts based on specific study criteria and physician discretion.

The purpose of this study is to assess the safety, tolerability, and early signs of efficacy of ziftomenib in combination with SOC drugs to treat AML.

03

Conditions studied

  • Acute Myeloid Leukemia
  • Mixed Lineage Leukemia Gene Mutation
  • Refractory AML
  • AML With Mutated NPM1
  • Acute Myeloid Leukemia Recurrent
  • Acute Myeloid Leukemia, in Relapse
  • NPM1 Mutation
  • KMT2Ar
  • Myeloid Sarcoma
  • Nucleophosmin 1-mutated Acute Myeloid Leukemia

Keywords

  • Leukemia
  • Myeloid
  • AML
  • Hematological malignancy
  • KMT2A
  • NPM1
  • Menin
  • Acute Leukemia
  • Newly diagnosed AML
  • Untreated AML
  • venetoclax
  • cytarabine
  • daunorubicin
  • KMT2A-r
  • NPM1 mutation
  • Refractory AML
  • Acute Myeloid Leukemia, in Relapse
  • quizartinib
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Key Inclusion Criteria:

  • Patients must have a documented NPM1 mutation or KMT2A rearrangement and have either newly diagnosed or AML

    • Those intending treatment with intensive chemotherapy in Arm C should be NPM1-m and FLT3-ITD+ with an allelic ratio ≥0.05 and eligible for FLT3-targeted treatment
  • (ECOG) performance status of 0, 1, or 2
  • Adequate liver, renal, and cardiac function according to protocol defined criteria
  • A female of must agree to use adequate as well as a double barrier method from the time of screening through 180 days following the last dose of study intervention. A male of childbearing potential must agree to use abstinence or use a double barrier method of contraception from the time of screening through 180 days following the last dose of study intervention

    • Female patients of childbearing potential who receive quizartinib in Arm C should use a highly effective method of contraception during quizartinib treatment and for 7 months after the last dose

Key Exclusion Criteria:

  • Diagnosis of either acute promyelocytic leukemia or blast phase chronic myeloid leukemia
  • Known history of BCR-ABL alteration
  • Advanced malignant hepatic tumor
  • Administration of within 14 days prior to, during, or after treatment until B-cell recovery
  • Active central nervous system (CNS) involvement by AML.
  • Clinical signs/symptoms of leukostasis or WBC > 25,000 / microliter. Hydroxyurea and/or leukapheresis and/or up to 2 doses of cytarabine if used per institutional SOC for control of leukocytosis are permitted to meet this criterion
  • Not recovered to Grade ≤1 ( v5.0) from all nonhematological toxicities except for alopecia
  • Known clinically active , active or active infection
  • For newly diagnosed cohorts: received prior chemotherapy for leukemia, except hydroxyurea and/or leukapheresis and/or up to 2 doses of cytarabine per institutional standards to control leukocytosis, or prior treatment with all-transretinoic acid for initially suspected acute promyelocytic leukemia
  • For relapsed/refractory cohorts: received chemotherapy, immunotherapy, radiotherapy, or any ancillary therapy that is considered to be \< 14 days prior to the first dose of ziftomenib or within 5 drug half-lives prior to the first dose of study drug
  • Uncontrolled intercurrent illness including, but not limited to, cardiac illness as defined in the protocol
  • Mean corrected for heart rate by Fredericia's formula (QTcF)

    • Arm A and Arm B: >480 ms on triplicate ECGs
    • Arm C: >450 ms on triplicate ECGs
  • Uncontrolled infection
  • Women who are pregnant or lactating
  • An active and currently receiving chemotherapy for that malignancy or disease that is uncontrolled/progressing
  • Patients who have active requiring >0.5 mg/kg prednisone or any new or increase in in the prior 2 weeks for GVHD treatment
Terms in these criteria, in plain language(14)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

GVHD (graft-versus-host disease)

After a transplant from a donor, the donor’s immune cells attack the recipient’s body, often the skin, gut or liver.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
420 participants (estimated)

Study arms

  • Experimental
    Dose Escalation: Ziftomenib with Venetoclax and Azacitidine in R/R NPM1-m (A-1)

    Ziftomenib with Venetoclax and Azacitidine in relapsed/refractory NPM1-m AML patients who have failed at least one prior line of therapy

    Drug: Ziftomenib · Drug: Venetoclax · Drug: Azacitidine

  • Experimental
    Dose Validation/Expansion: Ziftomenib with Venetoclax and Azacitidine in R/R NPM1-m (A-1)

    Ziftomenib with Venetoclax and Azacitidine in relapsed/refractory NPM1-m AML patients who have failed at least one prior line of therapy

    Drug: Ziftomenib · Drug: Venetoclax · Drug: Azacitidine

  • Experimental
    Dose Escalation: Ziftomenib with 7+3 in 1L NPM1-m/FLT3 wildtype (A-2)

    Ziftomenib with 7+3 in newly diagnosed NPM1-m AML patients who are candidates for intensive chemotherapy and must be FLT3 wildtype or ITD ratio \<0.05

    Drug: Ziftomenib · Drug: Daunorubicin · Drug: Cytarabine

  • Experimental
    Dose Validation/Expansion: Ziftomenib with 7+3 in 1L NPM1-m/FLT3 wildtype (A-2)

    Ziftomenib with 7+3 in newly diagnosed NPM1-m AML patients who are candidates for intensive chemotherapy and must be FLT3 wildtype or ITD ratio \<0.05

    Drug: Ziftomenib · Drug: Daunorubicin · Drug: Cytarabine

  • Experimental
    Dose Validation/Expansion: Ziftomenib with Venetoclax in R/R NPM1-m (A-3)

    Ziftomenib with Venetoclax in relapsed/refractory NPM1-m AML patients who have failed at least one prior line of therapy

    Drug: Ziftomenib · Drug: Venetoclax

  • Experimental
    Dose Validation/Expansion: Ziftomenib with Venetoclax and Azacitidine in 1L NPM1-m (A-4)

    Ziftomenib with Venetoclax and Azacitidine in newly diagnosed NPM1-m AML patients

    Drug: Ziftomenib · Drug: Venetoclax · Drug: Azacitidine

  • Experimental
    Dose Escalation: Ziftomenib with Venetoclax and Azacitidine in R/R KMT2A-r (B-1)

    Ziftomenib with Venetoclax and Azacitidine in relapsed/refractory KMT2A-r AML patients who have failed at least one prior line of therapy

    Drug: Ziftomenib · Drug: Venetoclax · Drug: Azacitidine

  • Experimental
    Dose Validation/Expansion: Ziftomenib with Venetoclax and Azacitidine in R/R KMT2A-r (B-1)

    Ziftomenib with Venetoclax and Azacitidine in relapsed/refractory KMT2A-r AML patients who have failed at least one prior line of therapy

    Drug: Ziftomenib · Drug: Venetoclax · Drug: Azacitidine

  • Experimental
    Dose Escalation: Ziftomenib with 7+3 in 1L KMT2A-r (B-2)

    Ziftomenib with 7+3 in newly diagnosed KMT2A-r AML patients who are candidates for intensive chemotherapy

    Drug: Ziftomenib · Drug: Daunorubicin · Drug: Cytarabine

  • Experimental
    Dose Validation/Expansion: Ziftomenib with 7+3 in 1L KMT2A-r (B-2)

    Ziftomenib with 7+3 in newly diagnosed KMT2A-r AML patients who are candidates for intensive therapy

    Drug: Ziftomenib · Drug: Daunorubicin · Drug: Cytarabine

  • Experimental
    Dose Validation/Expansion: Ziftomenib with Venetoclax + Azacitidine in 1L KMT2A-r (B-3)

    Ziftomenib with Venetoclax and Azacitidine in newly diagnosed KMT2A-r AML patients

    Drug: Ziftomenib · Drug: Venetoclax · Drug: Azacitidine

  • Experimental
    Dose Escalation: Ziftomenib with 7+3+quizartinib in 1L NPM1-m/FLT3-ITD+ AML patients (C-1)

    Ziftomenib with 7+3 and quizartinib in newly diagnosed NPM1-m and FLT3-ITD+ (with allelic ratio ≥0.05) AML patients who are candidates for IC and eligible to receive FLT3-targeted therapy

    Drug: Ziftomenib · Drug: Daunorubicin · Drug: Cytarabine · Drug: Quizartinib

  • Experimental
    Dose Validation/Expansion: Ziftomenib with 7+3+quizartinib in 1L NPM1-m/FLT3-ITD+ AML patients (C-1)

    Ziftomenib with 7+3 and quizartinib in newly diagnosed NPM1-m and FLT3-ITD+ (with allelic ratio ≥0.05) AML patients who are candidates for IC and eligible to receive FLT3-targeted therapy

    Drug: Ziftomenib · Drug: Daunorubicin · Drug: Cytarabine · Drug: Quizartinib

Interventions

  • Oral Administration

    Also known as: KO-539

  • Oral Administration

    Also known as: Venclexta, Venclyxto

  • Subcutaneous or Intravenous Administration

    Also known as: Azadine, Vidaza

  • Intravenous Administration

    Also known as: Cerubidine, daunomycin

  • Intravenous Administration

    Also known as: cytosine arabinoside (ara-C), Cytosar-U, Tarabine PFS

  • Oral Administration

    Also known as: Vanflyta

06

What researchers measure

Primary outcomes

  1. Rate of dose limiting toxicities (DLTs) per dose level (Part 1a only)

    Assessed by the NCI-CTCAE v5.0

    Time frame: During the first 28 days of ziftomenib in combination with SOC backbone treatment (1 cycle)

  2. Descriptive statistics of adverse events

    Assessed by the NCI-CTCAE v5.0

    Time frame: From Cycle 1 Day 1 up to and including 28 days following the end of 36 months of treatment

  3. Complete remission (CR) rate

    Assessed by the ELN 2022 criteria

    Time frame: Until relapse, new anti-cancer therapy, death, or up to 36 months of treatment, whichever occurs first

Secondary outcomes

  1. Composite Complete Remission (CRc)

    Assessed by the ELN 2022 criteria

    Time frame: Until relapse, new anti-cancer therapy, death, or up to 36 months of treatment, whichever occurs first

  2. Morphologic leukemia-free state (MLFS) rate

    Assessed by the ELN 2022 criteria

    Time frame: Until relapse, new anti-cancer therapy, death, or up to 36 months of treatment, whichever comes first

  3. Measurable residual disease (MRD)

    Assessed by multiparameter flow cytometry (MFC) and/or molecular analysis (NGS, PCR)

    Time frame: Until relapse, new anti-cancer therapy, death, or up to 36 months of treatment, whichever occurs first

  4. Median OS

    To assess overall survival of ziftomenib

    Time frame: From Cycle 1 Day 1 to date of death from any cause, assessed up to 36 months of treatment

  5. Proportion of patients alive

    To assess proportion of patients alive at 1 year following start of treatment with ziftomenib

    Time frame: From Cycle 1 Day 1 until death from any cause, assessed up to 1 year following start of treatment

  6. Median EFS

    To assess median event free survival

    Time frame: From Cycle 1 Day 1 to treatment failure, hematologic relapse following CR, or death from any cause, whichever comes first, assessed up to 36 months of treatment

  7. EFS

    To assess event free survival at 1 year

    Time frame: From Cycle 1 Day 1 to treatment failure, hematologic relapse following CR, or death from any cause, whichever comes first, assessed up to 1 year following start of treatment

  8. Median DOR

    To assess median duration of remission

    Time frame: From time of first remission to relapse or death, whichever occurs first, assessed up to 36 months from start of treatment

  9. Proportion of patients who undergo HSCT

    To assess proportion of patients who undergo hematopoietic stem cell transplant

    Time frame: From Cycle 1 Day 1 until date of HSCT, assessed up to 36 months of treatment

  10. TI

    To assess rate of transfusion independence

    Time frame: From 28 days prior to Cycle 1 Day 1 up to and including 28 days following the end of 36 months of treatment

  11. Cmax

    Maximum plasma concentration (Cmax) of ziftomenib and metabolites

    Time frame: Cycle 1; each cycle is 28 days

  12. Tmax

    Time to maximum plasma concentration (Tmax) of ziftomenib and metabolites

    Time frame: Cycle 1; each cycle is 28 days

  13. AUC0-last

    Area under the concentration-time curve from time zero to the time of the last quantifiable concentration after dosing (AUC0-last) of ziftomenib and metabolites

    Time frame: Cycle 1; each cycle is 28 days

  14. AUCtau

    Area under the concentration-time curve over a dosing interval (AUCtau) of ziftomenib

    Time frame: Cycle 1; each cycle is 28 days

  15. Accumulation ratio of ziftomenib and metabolites

    To assess accumulation ratio of ziftomenib and metabolites

    Time frame: Cycle 1; each cycle is 28 days

  16. Cmax of venetoclax

    Maximum plasma concentration (Cmax) of venetoclax

    Time frame: Cycle 1; each cycle is 28 days

  17. Tmax of venetoclax

    Time to maximum plasma concentration (Tmax) of venetoclax

    Time frame: Cycle 1; each cycle is 28 days

  18. AUC0-last of venetoclax

    Area under the concentration-time curve from time zero to the time of the last quantifiable concentration after dosing (AUC0-last) of venetoclax

    Time frame: Cycle 1; each cycle is 28 days

  19. AUCtau of venetoclax

    Area under the concentration-time curve over a dosing interval (AUCtau) of venetoclax

    Time frame: Cycle 1; each cycle is 28 days

  20. Cmax of quizartinib

    Maximum plasma concentration (Cmax) of quizartinib

    Time frame: Cycle 1; each cycle is 28 days

  21. Tmax of quizartinib

    Time to maximum plasma concentration (Tmax) of quizartinib

    Time frame: Cycle 1; each cycle is 28 days

  22. AUC0-last of quizartinib

    Area under the concentration-time curve from time zero to the time of the last quantifiable concentration after dosing (AUC0-last) of quizartinib

    Time frame: Cycle 1; each cycle is 28 days

  23. AUCtau of quizartinib

    Area under the concentration-time curve over a dosing interval (AUCtau) of quizartinib

    Time frame: Cycle 1; each cycle is 28 days

07

Study locations

44 of 44 sites recruiting
08

References and documents

Publications

  • Wang ES, Erba HP, Zeidan AM, Roboz GJ, Altman JK, Advani AS, Lin TL, Strickland SA, Juckett MB, Pratz KW, Mangan JK, McMahon CM, Alsfeld LC, Balasubramanian SK, Guru Murthy GS, Rotta M, Palmisiano N, McCloskey J, Saliba AN, Khawandanah M, Madanat YF, Naqvi K, Qasrawi AH, Schiller GJ, Badar T, Gojo I, Yaghmour G, Osman D, Zhang H, Tian Y, Soifer HS, Riches M, Corum D, Leoni M, Fathi AT, Issa GC. Ziftomenib with venetoclax and azacitidine in relapsed/refractory NPM1-mutated acute myeloid leukemia. Blood. 2026 Jun 2:blood.2026034043. doi: 10.1182/blood.2026034043. Online ahead of print. PubMed 42227701 ↗

Individual participant data

Plan to share: No

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jul 2023 (actual). Primary completion is estimated for Apr 2030, 81 months after the start.

Of 183 industry-sponsored phase 1 interventional studies under Leukemia, Myeloid, Acute, half reached primary completion within 40 months of starting (the median), counting those still running; a quarter within 29 and three quarters within 62. This study's planned 81 months is above that.

Counting every sponsor, half of 491 studies reached it within 49 months; a quarter within 31 and three quarters within 77.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 9, 2023
First posted
Feb 21, 2023
StartActual
Jul 18, 2023
Primary completionEst.
Apr 2030
CompletionEst.
Apr 2030
Last update
Mar 13, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 13, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05735184
Lead sponsor
Kura Oncology, Inc.
Responsible party
Sponsor
First posted
Feb 21, 2023
Start date
Jul 18, 2023
Primary completion
Apr 2030 (estimated)
Completion
Apr 2030 (estimated)
Last update
Mar 13, 2026

Study contacts

Kura Medical Information
Contact
medinfo@kuraoncology.com
844-KURAONC ext. (844-587-2662)

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Quizartinib

Start the discussion